The company have substantially advanced this development of the novel therapy for cardiac amyloidosis, leveraging Attruby. Initial patient information reveals significant benefits for those suffering with a debilitating disease. This emphasis represents BridgeBio's focus to managing significant healthcare needs in a heart disease arena. … Read More